V-Lap System Gives More Power to HF Patients

Vectorious Medical Technologies is hoping its V-Lap System can help patients manage heart failure (HF) differently. The Tel Aviv, Israel-based company said it has enrolled the first six patients in its VECTOR-HF II study.

The trial, which was launched in January, is looking at the company’s V-Lap System. Plans call for the study to enroll up to 20 patients. If successful, then the lessons learned from VECTOR-HF II will be incorporated into VECTOR-HF III, a larger pivotal study that is scheduled to begin in the U.S. in 2023 with the goal of achieving FDA approval.

The V-LAP in-heart implantable sensor technology allows for the self-management for detecting and managing HF early before it further damages the heart. Direct pressure readings from the left atrium (LA), captured by the V-LAP sensor, will be visible to both physicians and patients using dedicated apps for the patient and for the clinic.

When LA pressure is out of the optimal range, patients are guided to adjust diuretics based on the predefined treatment plan. If the LA pressure is in suboptimal ranges, the medical team is notified and can provide additional instructions to prevent further deterioration.

“The V-LAP System is the first wireless digital platform that enables chronic HF patients to manage their disease by titrating the dosing of their medication directly in response to accurate, very early detection of fluid accumulation,” said Vectorious CEO and co-founder Eyal Orion, MD. “The successful completion of the VECTOR-HF I study and the launch of the VECTOR-HF II study are exciting milestones for Vectorious and for patients suffering from severe, chronic HF, and the culmination of more than a decade of development work required to enable placing a digital sensor directly in the heart. We strongly believe that the unique data from the heart’s LA, coupled with our technological platform, which enables millions of HF patients to take ownership of their disease, is the right and only way to transform treatment paradigm.”